Skip to content
naulon

Not checkedNot checked for notices yet.

Expression and Significance of Raf Kinase Inhibitory Protein in Lung Cancer

Dayun YANG, Zhan QI

Chinese Journal of Lung Cancer · 2012

doi:10.3779/j.issn.1009-3419.2012.10.06 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Background and objective Raf kinase inhibitory protein (RKIP) belongs to the phosphatidylethanolamine binding protein family. RKIP is an endogenous inhibitor of the ERK/MAPK, NF-κΒ, and G protein-coupled receptor signaling pathways. This study aims to investigate the expression of RKIP in non-small cell lung cancer (NSCLC) and to determine the association of RKIP expression with the clinicopathologic features of NSCLC. Methods Reverse transcription-polymerase chain reaction, Western blot, and immunohistochemistry were used to detect RKIP expression in 83 specimens with NSCLC and normal lung tissues and to analyze the association of RKIP expression with the clinicopathologic features of NSCLC. All cases were confirmed by pathological diagnosis, and primary tumors were not found at other sites. No medical records of preoperative radiotherapy, chemotherapy, and immunotherapy were found in the groups. Results RKIP expression was down-regulated significantly in NSCLC compared with adjacent cancer tissues (P<0.05). It was associated with differentiation, pathological tumor-node-metastasis stage, survival time, and lympho invasion (P<0.05) but not with gender, smoking status, age, tumor size, and histologic type (P>0.05). Conclusion The deficiency of RKIP expression is positively correlated with carcinogenesis and invasion metastasis of NSCLC. RKIP is a potential marker and target for clinic therapy.

Abstract licence: CC BY

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.